www.captodayonline.com
Open in
urlscan Pro
192.124.249.164
Public Scan
Submitted URL: http://captodayonline.com/
Effective URL: https://www.captodayonline.com/
Submission: On June 06 via api from IT — Scanned from IT
Effective URL: https://www.captodayonline.com/
Submission: On June 06 via api from IT — Scanned from IT
Form analysis 1 forms found in the DOM
GET https://www.captodayonline.com/
<form method="get" id="searchform" action="https://www.captodayonline.com/">
<button class="search-button" type="submit" value="Search"></button>
<input type="text" id="s" name="s" value="Search..." onfocus="if (this.value == 'Search...') {this.value = '';}" onblur="if (this.value == '') {this.value = 'Search...';}">
</form>Text Content
TOP NEWS
Epredia SlideMate Laser gets MedTech Breakthrough Award
CAP TODAY PATHOLOGY/LABORATORY MEDICINE/LABORATORY MANAGEMENT
* Home
* ALL ISSUES
* IN THIS MONTH’S ISSUE
* 2024 issues
* January 2024
* February 2024
* March 2024
* April 2024
* May 2024
* 2023 Issues
* January 2023
* February 2023
* March 2023
* April 2023
* May 2023
* June 2023
* July 2023
* August 2023
* September 2023
* October 2023
* November 2023
* December 2023
* 2022 Issues
* January 2022
* February 2022
* March 2022
* April 2022
* May 2022
* June 2022
* July 2022
* August 2022
* September 2022
* October 2022
* November 2022
* December 2022
* 2021 Issues
* January 2021
* February 2021
* March 2021
* April 2021
* May 2021
* June 2021
* July 2021
* August 2021
* September 2021
* October 2021
* November 2021
* December 2021
* 2020 Issues
* January 2020
* February 2020
* March 2020
* April 2020
* May 2020
* June 2020
* July 2020
* August 2020
* September 2020
* October 2020
* November 2020
* December 2020
* 2019 Issues
* January 2019
* February 2019
* March 2019
* April 2019
* May 2019
* June 2019
* July 2019
* August 2019
* September 2019
* October 2019
* November 2019
* December 2019
* 2018 Issues
* January 2018
* February 2018
* March 2018
* April 2018
* May 2018
* June 2018
* July 2018
* August 2018
* September 2018
* October 2018
* November 2018
* December 2018
* 2017 Issues
* January 2017
* February 2017
* March 2017
* April 2017
* May 2017
* June 2017
* July 2017
* August 2017
* September 2017
* October 2017
* November 2017
* December 2017
* 2016 Issues
* January 2016
* February 2016
* March 2016
* April 2016
* May 2016
* June 2016
* July 2016
* August 2016
* September 2016
* October 2016
* November 2016
* December 2016
* 2015 Issues
* January 2015
* February 2015
* March 2015
* April 2015
* May 2015
* June 2015
* July 2015
* August 2015
* September 2015
* October 2015
* November 2015
* December 2015
* 2014 Issues
* January 2014
* February 2014
* March 2014
* April 2014
* May 2014
* June 2014
* July 2014
* August 2014
* September 2014
* October 2014
* November 2014
* December 2014
* 2013 Issues
* January 2013
* February 2013
* March 2013
* April 2013
* May 2013
* June 2013
* July 2013
* August 2013
* September 2013
* October 2013
* November 2013
* December 2013
* Subspecialties
* Clinical Chemistry
* Clinical Pathology
* Coagulation
* Cytology
* Hematology
* Hematopathology
* Histotechnology
* Immunoassay
* Immunology
* Information Technology
* Microbiology
* Molecular Pathology
* Pathology
* Point-of-Care Testing
* Product Guides
* Anatomic Pathology
* Automated Molecular
* Bedside Glucose Testing Systems
* Billing/Accounts Receivable/RCM Systems
* Chemistry and Immunoassay Analyzers for POC and Low-Volume Labs
* Chemistry and immunoassay analyzers for high-volume labs
* Coagulation Analyzers
* Coagulation Analyzers POC, Self-Monitoring
* Hematology Analyzers
* Laboratory Automation Systems and Workcells
* Laboratory Information Systems
* Next-Gen Sequencing Systems
* Urinalysis Instrumentation
* Jobs
* Advertising
* Current Advertisers
* 2024 Ad Rates
* WEBINARS
* Marketplace
* Contact Us
* Contact Us
* Submit Q&A question
* Submit Letter to Editor
* Submit your lab’s problem/solution
* Subscribe
* EVENTS FOR PATHOLOGISTS
Go to... Home ALL ISSUES – IN THIS MONTH’S ISSUE – 2024 issues –
– January 2024 – – February 2024 – – March 2024 – – April
2024 – – May 2024 – 2023 Issues – – January 2023 –
– February 2023 – – March 2023 – – April 2023 – – May 2023
– – June 2023 – – July 2023 – – August 2023 – – September
2023 – – October 2023 – – November 2023 – – December 2023
– 2022 Issues – – January 2022 – – February 2022 – – March
2022 – – April 2022 – – May 2022 – – June 2022 – – July
2022 – – August 2022 – – September 2022 – – October 2022 –
– November 2022 – – December 2022 – 2021 Issues – – January
2021 – – February 2021 – – March 2021 – – April 2021 –
– May 2021 – – June 2021 – – July 2021 – – August 2021 –
– September 2021 – – October 2021 – – November 2021 –
– December 2021 – 2020 Issues – – January 2020 – – February
2020 – – March 2020 – – April 2020 – – May 2020 – – June
2020 – – July 2020 – – August 2020 – – September 2020 –
– October 2020 – – November 2020 – – December 2020 – 2019 Issues
– – January 2019 – – February 2019 – – March 2019 –
– April 2019 – – May 2019 – – June 2019 – – July 2019 –
– August 2019 – – September 2019 – – October 2019 – – November
2019 – – December 2019 – 2018 Issues – – January 2018 –
– February 2018 – – March 2018 – – April 2018 – – May 2018
– – June 2018 – – July 2018 – – August 2018 – – September
2018 – – October 2018 – – November 2018 – – December 2018
– 2017 Issues – – January 2017 – – February 2017 – – March
2017 – – April 2017 – – May 2017 – – June 2017 – – July
2017 – – August 2017 – – September 2017 – – October 2017 –
– November 2017 – – December 2017 – 2016 Issues – – January
2016 – – February 2016 – – March 2016 – – April 2016 –
– May 2016 – – June 2016 – – July 2016 – – August 2016 –
– September 2016 – – October 2016 – – November 2016 –
– December 2016 – 2015 Issues – – January 2015 – – February
2015 – – March 2015 – – April 2015 – – May 2015 – – June
2015 – – July 2015 – – August 2015 – – September 2015 –
– October 2015 – – November 2015 – – December 2015 – 2014 Issues
– – January 2014 – – February 2014 – – March 2014 –
– April 2014 – – May 2014 – – June 2014 – – July 2014 –
– August 2014 – – September 2014 – – October 2014 – – November
2014 – – December 2014 – 2013 Issues – – January 2013 –
– February 2013 – – March 2013 – – April 2013 – – May 2013
– – June 2013 – – July 2013 – – August 2013 – – September
2013 – – October 2013 – – November 2013 – – December
2013 Subspecialties – Clinical Chemistry – Clinical Pathology
– Coagulation – Cytology – Hematology – Hematopathology
– Histotechnology – Immunoassay – Immunology – Information Technology
– Microbiology – Molecular Pathology – Pathology – Point-of-Care
Testing Product Guides – Anatomic Pathology – Automated Molecular
– Bedside Glucose Testing Systems – Billing/Accounts Receivable/RCM Systems
– Chemistry and Immunoassay Analyzers for POC and Low-Volume Labs
– Chemistry and immunoassay analyzers for high-volume labs – Coagulation
Analyzers – Coagulation Analyzers POC, Self-Monitoring – Hematology
Analyzers – Laboratory Automation Systems and Workcells – Laboratory
Information Systems – Next-Gen Sequencing Systems – Urinalysis
Instrumentation Jobs Advertising – Current Advertisers – 2024 Ad
Rates WEBINARS Marketplace Contact Us – Contact Us – Submit Q&A question
– Submit Letter to Editor – Submit your lab’s
problem/solution Subscribe EVENTS FOR PATHOLOGISTS
MAY 2024
* CLIMATE OF CONCERN OVER FUNGAL INFECTIONS
May 2024—If anything keeps Arturo Casadevall, MD, PhD, lying awake at night,
it’s the frogs. And the bats. Also, the patients (relatively few, at least
for now) who are affected by invasive fungal diseases. Dr. Casadevall is a
microbiologist and infectious diseases expert in the Johns Hopkins Division
of Infectious Diseases, Department of Medicine, and the Bloomberg School of
Public Health, where he’s a professor of medicine and chairs the Department
of Molecular Microbiology and Immunology. In his waking hours, he looks
deeply and broadly at the natural world and how the disturbing growth of
fungal infections might impact the medical world. Though the arrows haven’t
hit the bull’s-eye, they seem to be flying in that direction, says Dr.
Casadevall, who has written widely on this topic, including “Immunity to
Invasive Fungal Diseases.” In a recent interview with CAP TODAY, Dr.
Casadevall spoke about how he and others in the field are thinking about how
medicine might respond to this potential threat.
Read More »
* DIGGING INTO THE INTERPRETATION OF TSH RESULTS
May 2024—In a time of wellness testing and high rates of levothyroxine
prescribing for hypothyroidism, it may also be time to rethink TSH test
result interpretation.
* CORE LAB EFFICIENCIES IN MONOCLONAL GAMMOPATHY TESTING
May 2024—Many laboratories have brought order to chaos in test ordering by
launching initiatives to do so, for cost and staff savings and patient care
benefits. TriCore is one—it set its sights on orders for monoclonal
gammopathies.
* LUPUS ANTICOAGULANT—PROFICIENCY TEST AND PREANALYTICS
May 2024—What is a lupus anticoagulant (LA)? LA is somewhat of a misnomer.
Many patients with this condition do not have systemic lupus erythematosus
(SLE) and usually do not bleed. However, the in vitro phenomenon was
originally described in patients with SLE, as well as other autoimmune
disorders—thus use of the term “lupus,” and this does often lead to prolonged
in vitro coagulation testing—thus use of the term “anticoagulant.”
Image Credits: [do_widget id=enhancedtextwidget-12].
VIDEO SPOTLIGHT
* WHAT IS FLOCK? FIND OUT WHAT MAKES PURITAN® FLOCKED SWABS SO SPECIAL.
Puritan® patented flocked swabs are super collectors! PurFlock Ultra® and
HydraFlock® flocked swabs, incorporating intricate fiber technology, are
developed and designed for increased absorbency and elution capacity. LEARN
MORE.
Read More »
COMING IN THE JUNE ISSUE
* FIRST LOOKS AND FAST TAKES ON LDT FINAL RULE
June 2024—The Food and Drug Administration’s final rule on
laboratory-developed tests was released April 29 and published May 6. Shortly
after, Compass Group laboratory leaders met online with CAP TODAY publisher
Bob McGonnagle, who asked for their early reactions to what they heard and
read. Among the categories for which the FDA has indicated its intent to
exercise partial enforcement discretion are LDTs manufactured and performed
by a laboratory that is integrated within a health system and that meet an
unmet medical need. Here, this month, is the conversation that took place in
early May. Next month we will publish our story on the final rule and the
views of others. The Compass Group is an organization of not-for-profit IDN
system lab leaders who collaborate to identify and share best practices and
strategies.
Read More »
CAP TODAY RECOMMENDS
* CLINICAL LAB 2.0 HONORS LABORATORY TEAM EXCELLENCE
Clinical Lab 2.0, a Project Santa Fe Foundation initiative, released a
proclamation during Medical Laboratory Professionals Week, April 14–20, to
recognize and celebrate the roles of laboratory medicine and pathology in the
field of medicine “as we transition from the business of volume to the
business of value” in the delivery of integrated health care. Read the full
proclamation here. Clinical Lab 2.0 was established to provide thought
leadership and help develop the evidence base for the valuation of clinical
laboratory services in the next era of global health care.
Read More »
CAP TODAY WEBINARS ON-DEMAND
* LIQUID BIOPSY AND CONCURRENT TESTING STRATEGIES FOR PATIENTS WITH METASTATIC
NSCLC
Webinar presenter Zin Htway, PhD, Supervisor and Operations Manager, Anatomic
Pathology as HCA Los Robles Hospital and Medical Center, discusses the impact
of liquid biopsy and concurrent biomarker testing for the appropriate care of
patients with NSCLC .
Read More »
REGISTER NOW
* REGISTER FOR OUR UPCOMING WEBINAR
Genomic profile availability impact on NSCLC patient outcomes in real world
study and daily practice
Thursday, June 13, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Melina Marmarelis, MD, MSCE, and Salvatore Fortunato
Priore, MD, PhD, will discuss a real-world study cohort utilizing electronic
health records to assess the impact of the availability of genomic profiles
on guiding first-line therapy and patient outcomes. They found that the
availability of molecular genotyping results before first-line therapy was
associated with significantly better overall survival, and that concurrent
tissue and plasma testing was associated with higher odds of availability of
results before first-line therapy.
Read More »
* Register for our upcoming webinar
Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic
Mastocytosis
June 25, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical
Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor
University of Utah, Medical Director Hematopathology and
Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of
Medicine, Uniformed Services University Allergy Division Director will
discuss the barriers and possible solutions to screening for and diagnosing
Systemic Mastocytosis (SM) and recommendations that will empower
cross-functional laboratory stakeholders to implement changes that can help
improve the diagnosis of SM.
Image Credits: [do_widget id=enhancedtextwidget-12].
AMP CASE REPORTS
* AMP CASE REPORT: USE OF MOLECULAR TECHNIQUES TO SOLVE A CHALLENGING CASE OF
PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA
April 2024—Primary cutaneous marginal zone lymphoma (PCMZL) is a newly
recognized, distinctive subtype of non-Hodgkin’s lymphoma. This low-grade
lymphoma predominantly presents as papules or nodules within the skin of
middle-aged adults. Formerly grouped under the extranodal marginal zone
lymphoma (EMZL) category, the World Health Organization’s fifth edition
classification of hematolymphoid tumors now recognizes PCMZL as a distinct
entity.
Read More »
* AMP CASE REPORT: ACUTE MYELOID LEUKEMIA WITH HYPERDIPLOIDY
* AMP CASE REPORT: POTENTIAL VON HIPPEL-LINDAU SYNDROME IN A PATIENT WITH
NEGATIVE GERMLINE TESTING
* AMP CASE REPORT: IDENTIFICATION OF MULTIPLE GERMLINE CANCER PREDISPOSING GENE
VARIANTS IN A SINGLE PATIENT DURING TUMOR SEQUENCING ANALYSIS
* AMP CASE REPORT: LUNG MICROPAPILLARY ADENOCARCINOMAS REVISITED
RECENT JOBS
Access to industry specific jobs! The career center is a cohesive destination
for CAP members and nonmembers to connect with prospective employers and
employees in the laboratory industry.
Assistant - Professor - Hematopathologist
Aurora, CO
CU Anschutz School of Medicine
Gynecologic Pathologist
Burlington, MA
https://www.linkedin.com/company/beth-israel-lahey-health/mycompany/
Chief of Pathology
Cambridge, MA
Chief of Pathology
Pathologist
Green Bay, WI
Prevea Health
Hematopathologist, Las Vegas, NV
Las Vegas, NV
Quest Diagnostics
View All Jobs
SUBSCRIBE
INDUSTRY NEWS
Epredia SlideMate Laser gets MedTech Breakthrough Award
June 3, 2024—MedTech Breakthrough announced that Epredia has been selected as
the winner of best new technology solution—pathology for its SlideMate Laser
printer in the 8th a...
ACLA challenges FDA final rule to regulate LDTs
May 29, 2024—The American Clinical Laboratory Association and its member
company, HealthTrackRx, filed a lawsuit today against the U.S. Food and Drug
Administration in the U.S....
FDA clears BioMérieux Vidas TBI test
May 28, 2024—BioMérieux received FDA 510(k) clearance for its Vidas TBI (GFAP,
UCH-L1), a serum-based test that supports the assessment of patients with mild
traumatic brain inj...
MARKETPLACE
LEICA PUBLISHES GUIDE TO GOOD HISTOLOGY PRACTICE
May 2024—Leica Biosystems has published “101 Steps to Better Histology—A
Practical Guide to Good Histology Practice,” written by histology consultant
Geoffrey Rolls. The guide provides practical advice on best-practice techniques
and simple ways to avoid common errors and covers each aspect of the histology
process: specimen collection, grossing, processing, embedding, and sectioning
and staining. It is downloadable free of charge on Leica’s “Knowledge Pathway”
site.
Read more >>
QUANTIMETRIX DIPPER POCT NOW WITH INTEGRATED BARCODE
May 2024—Quantimetrix announced that its Dipper POCT urinalysis dipstick control
pouches now include a barcode. The integrated barcode is designed to streamline
the workflow and reduce errors that can arise from manually entering lot numbers
and expiration dates. Dipper POCT kits contain ready-to-use, single-use plastic
pouches in two levels, each filled with 1.5 mL of liquid control material. The
product is stable for three months at room temperature and up to three years at
2º to 8ºC. Read more >>
FDA CLEARS PATHFAST POC HS-CTNI TEST
May 2024—Polymedco announced FDA 510(k) clearance of the Pathfast hs-cTnI-II, a
high-sensitivity cardiac troponin assay for the diagnosis of myocardial
infarction at the point of care. The test delivers results in 17 minutes on the
Pathfast Biomarker analyzer using whole blood and plasma samples. Read more >>
PIXCELL ADDS DISTRIBUTION PARTNERS IN THE U.S.
May 2024—PixCell Medical announced a strategic distribution partnership with
Medline, Henry Schein, and Thermo Fisher Scientific to increase accessibility to
its flagship product, the HemoScreen point-of-care, five-part differential CBC
analyzer, in the United States. The FDA-cleared analyzer can be used with
capillary or venous anticoagulated whole blood and provides results in five
minutes. Read more >>
NEWCOMER SUPPLY TO DISTRIBUTE HISTOCYTE CELL LINE CONTROLS
May 2024—Newcomer Supply announced it is distributing HistoCyte Laboratories
cell line controls for research use only. HistoCyte uses proprietary methods to
process cell lines into tissue-like controls. The products are standardized,
developed, and manufactured to provide consistent morphology and staining
results throughout the FFPE block. Cell line controls are available as either
precut slides or in cell microarray blocks. Read more >>
RELATED POSTS
MAY 2024
* CLIMATE OF CONCERN OVER FUNGAL INFECTIONS
May 2024—If anything keeps Arturo Casadevall, MD, PhD, lying awake at night,
it’s the frogs. And the bats. Also, the patients (relatively few, at least
for now) who are affected by invasive fungal diseases. Dr. Casadevall is a
microbiologist and infectious diseases expert in the Johns Hopkins Division
of Infectious Diseases, Department of Medicine, and the Bloomberg School of
Public Health, where he’s a professor of medicine and chairs the Department
of Molecular Microbiology and Immunology. In his waking hours, he looks
deeply and broadly at the natural world and how the disturbing growth of
fungal infections might impact the medical world. Though the arrows haven’t
hit the bull’s-eye, they seem to be flying in that direction, says Dr.
Casadevall, who has written widely on this topic, including “Immunity to
Invasive Fungal Diseases.” In a recent interview with CAP TODAY, Dr.
Casadevall spoke about how he and others in the field are thinking about how
medicine might respond to this potential threat.
Read More »
* DIGGING INTO THE INTERPRETATION OF TSH RESULTS
May 2024—In a time of wellness testing and high rates of levothyroxine
prescribing for hypothyroidism, it may also be time to rethink TSH test
result interpretation.
* CORE LAB EFFICIENCIES IN MONOCLONAL GAMMOPATHY TESTING
May 2024—Many laboratories have brought order to chaos in test ordering by
launching initiatives to do so, for cost and staff savings and patient care
benefits. TriCore is one—it set its sights on orders for monoclonal
gammopathies.
* LUPUS ANTICOAGULANT—PROFICIENCY TEST AND PREANALYTICS
May 2024—What is a lupus anticoagulant (LA)? LA is somewhat of a misnomer.
Many patients with this condition do not have systemic lupus erythematosus
(SLE) and usually do not bleed. However, the in vitro phenomenon was
originally described in patients with SLE, as well as other autoimmune
disorders—thus use of the term “lupus,” and this does often lead to prolonged
in vitro coagulation testing—thus use of the term “anticoagulant.”
Image Credits: [do_widget id=enhancedtextwidget-12].
VIDEO SPOTLIGHT
* WHAT IS FLOCK? FIND OUT WHAT MAKES PURITAN® FLOCKED SWABS SO SPECIAL.
Puritan® patented flocked swabs are super collectors! PurFlock Ultra® and
HydraFlock® flocked swabs, incorporating intricate fiber technology, are
developed and designed for increased absorbency and elution capacity. LEARN
MORE.
Read More »
COMING IN THE JUNE ISSUE
* FIRST LOOKS AND FAST TAKES ON LDT FINAL RULE
June 2024—The Food and Drug Administration’s final rule on
laboratory-developed tests was released April 29 and published May 6. Shortly
after, Compass Group laboratory leaders met online with CAP TODAY publisher
Bob McGonnagle, who asked for their early reactions to what they heard and
read. Among the categories for which the FDA has indicated its intent to
exercise partial enforcement discretion are LDTs manufactured and performed
by a laboratory that is integrated within a health system and that meet an
unmet medical need. Here, this month, is the conversation that took place in
early May. Next month we will publish our story on the final rule and the
views of others. The Compass Group is an organization of not-for-profit IDN
system lab leaders who collaborate to identify and share best practices and
strategies.
Read More »
CAP TODAY RECOMMENDS
* CLINICAL LAB 2.0 HONORS LABORATORY TEAM EXCELLENCE
Clinical Lab 2.0, a Project Santa Fe Foundation initiative, released a
proclamation during Medical Laboratory Professionals Week, April 14–20, to
recognize and celebrate the roles of laboratory medicine and pathology in the
field of medicine “as we transition from the business of volume to the
business of value” in the delivery of integrated health care. Read the full
proclamation here. Clinical Lab 2.0 was established to provide thought
leadership and help develop the evidence base for the valuation of clinical
laboratory services in the next era of global health care.
Read More »
CAP TODAY WEBINARS ON-DEMAND
* LIQUID BIOPSY AND CONCURRENT TESTING STRATEGIES FOR PATIENTS WITH METASTATIC
NSCLC
Webinar presenter Zin Htway, PhD, Supervisor and Operations Manager, Anatomic
Pathology as HCA Los Robles Hospital and Medical Center, discusses the impact
of liquid biopsy and concurrent biomarker testing for the appropriate care of
patients with NSCLC .
Read More »
REGISTER NOW
* REGISTER FOR OUR UPCOMING WEBINAR
Genomic profile availability impact on NSCLC patient outcomes in real world
study and daily practice
Thursday, June 13, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Melina Marmarelis, MD, MSCE, and Salvatore Fortunato
Priore, MD, PhD, will discuss a real-world study cohort utilizing electronic
health records to assess the impact of the availability of genomic profiles
on guiding first-line therapy and patient outcomes. They found that the
availability of molecular genotyping results before first-line therapy was
associated with significantly better overall survival, and that concurrent
tissue and plasma testing was associated with higher odds of availability of
results before first-line therapy.
Read More »
* Register for our upcoming webinar
Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic
Mastocytosis
June 25, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical
Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor
University of Utah, Medical Director Hematopathology and
Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of
Medicine, Uniformed Services University Allergy Division Director will
discuss the barriers and possible solutions to screening for and diagnosing
Systemic Mastocytosis (SM) and recommendations that will empower
cross-functional laboratory stakeholders to implement changes that can help
improve the diagnosis of SM.
Image Credits: [do_widget id=enhancedtextwidget-12].
AMP CASE REPORTS
* AMP CASE REPORT: USE OF MOLECULAR TECHNIQUES TO SOLVE A CHALLENGING CASE OF
PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA
April 2024—Primary cutaneous marginal zone lymphoma (PCMZL) is a newly
recognized, distinctive subtype of non-Hodgkin’s lymphoma. This low-grade
lymphoma predominantly presents as papules or nodules within the skin of
middle-aged adults. Formerly grouped under the extranodal marginal zone
lymphoma (EMZL) category, the World Health Organization’s fifth edition
classification of hematolymphoid tumors now recognizes PCMZL as a distinct
entity.
Read More »
* AMP CASE REPORT: ACUTE MYELOID LEUKEMIA WITH HYPERDIPLOIDY
* AMP CASE REPORT: POTENTIAL VON HIPPEL-LINDAU SYNDROME IN A PATIENT WITH
NEGATIVE GERMLINE TESTING
* AMP CASE REPORT: IDENTIFICATION OF MULTIPLE GERMLINE CANCER PREDISPOSING GENE
VARIANTS IN A SINGLE PATIENT DURING TUMOR SEQUENCING ANALYSIS
* AMP CASE REPORT: LUNG MICROPAPILLARY ADENOCARCINOMAS REVISITED
MAY 2024
* CLIMATE OF CONCERN OVER FUNGAL INFECTIONS
May 2024—If anything keeps Arturo Casadevall, MD, PhD, lying awake at night,
it’s the frogs. And the bats. Also, the patients (relatively few, at least
for now) who are affected by invasive fungal diseases. Dr. Casadevall is a
microbiologist and infectious diseases expert in the Johns Hopkins Division
of Infectious Diseases, Department of Medicine, and the Bloomberg School of
Public Health, where he’s a professor of medicine and chairs the Department
of Molecular Microbiology and Immunology. In his waking hours, he looks
deeply and broadly at the natural world and how the disturbing growth of
fungal infections might impact the medical world. Though the arrows haven’t
hit the bull’s-eye, they seem to be flying in that direction, says Dr.
Casadevall, who has written widely on this topic, including “Immunity to
Invasive Fungal Diseases.” In a recent interview with CAP TODAY, Dr.
Casadevall spoke about how he and others in the field are thinking about how
medicine might respond to this potential threat.
Read More »
* DIGGING INTO THE INTERPRETATION OF TSH RESULTS
May 2024—In a time of wellness testing and high rates of levothyroxine
prescribing for hypothyroidism, it may also be time to rethink TSH test
result interpretation.
* CORE LAB EFFICIENCIES IN MONOCLONAL GAMMOPATHY TESTING
May 2024—Many laboratories have brought order to chaos in test ordering by
launching initiatives to do so, for cost and staff savings and patient care
benefits. TriCore is one—it set its sights on orders for monoclonal
gammopathies.
* LUPUS ANTICOAGULANT—PROFICIENCY TEST AND PREANALYTICS
May 2024—What is a lupus anticoagulant (LA)? LA is somewhat of a misnomer.
Many patients with this condition do not have systemic lupus erythematosus
(SLE) and usually do not bleed. However, the in vitro phenomenon was
originally described in patients with SLE, as well as other autoimmune
disorders—thus use of the term “lupus,” and this does often lead to prolonged
in vitro coagulation testing—thus use of the term “anticoagulant.”
Image Credits: [do_widget id=enhancedtextwidget-12].
VIDEO SPOTLIGHT
* WHAT IS FLOCK? FIND OUT WHAT MAKES PURITAN® FLOCKED SWABS SO SPECIAL.
Puritan® patented flocked swabs are super collectors! PurFlock Ultra® and
HydraFlock® flocked swabs, incorporating intricate fiber technology, are
developed and designed for increased absorbency and elution capacity. LEARN
MORE.
Read More »
COMING IN THE JUNE ISSUE
* FIRST LOOKS AND FAST TAKES ON LDT FINAL RULE
June 2024—The Food and Drug Administration’s final rule on
laboratory-developed tests was released April 29 and published May 6. Shortly
after, Compass Group laboratory leaders met online with CAP TODAY publisher
Bob McGonnagle, who asked for their early reactions to what they heard and
read. Among the categories for which the FDA has indicated its intent to
exercise partial enforcement discretion are LDTs manufactured and performed
by a laboratory that is integrated within a health system and that meet an
unmet medical need. Here, this month, is the conversation that took place in
early May. Next month we will publish our story on the final rule and the
views of others. The Compass Group is an organization of not-for-profit IDN
system lab leaders who collaborate to identify and share best practices and
strategies.
Read More »
CAP TODAY RECOMMENDS
* CLINICAL LAB 2.0 HONORS LABORATORY TEAM EXCELLENCE
Clinical Lab 2.0, a Project Santa Fe Foundation initiative, released a
proclamation during Medical Laboratory Professionals Week, April 14–20, to
recognize and celebrate the roles of laboratory medicine and pathology in the
field of medicine “as we transition from the business of volume to the
business of value” in the delivery of integrated health care. Read the full
proclamation here. Clinical Lab 2.0 was established to provide thought
leadership and help develop the evidence base for the valuation of clinical
laboratory services in the next era of global health care.
Read More »
CAP TODAY WEBINARS ON-DEMAND
* LIQUID BIOPSY AND CONCURRENT TESTING STRATEGIES FOR PATIENTS WITH METASTATIC
NSCLC
Webinar presenter Zin Htway, PhD, Supervisor and Operations Manager, Anatomic
Pathology as HCA Los Robles Hospital and Medical Center, discusses the impact
of liquid biopsy and concurrent biomarker testing for the appropriate care of
patients with NSCLC .
Read More »
REGISTER NOW
* REGISTER FOR OUR UPCOMING WEBINAR
Genomic profile availability impact on NSCLC patient outcomes in real world
study and daily practice
Thursday, June 13, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Melina Marmarelis, MD, MSCE, and Salvatore Fortunato
Priore, MD, PhD, will discuss a real-world study cohort utilizing electronic
health records to assess the impact of the availability of genomic profiles
on guiding first-line therapy and patient outcomes. They found that the
availability of molecular genotyping results before first-line therapy was
associated with significantly better overall survival, and that concurrent
tissue and plasma testing was associated with higher odds of availability of
results before first-line therapy.
Read More »
* Register for our upcoming webinar
Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic
Mastocytosis
June 25, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical
Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor
University of Utah, Medical Director Hematopathology and
Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of
Medicine, Uniformed Services University Allergy Division Director will
discuss the barriers and possible solutions to screening for and diagnosing
Systemic Mastocytosis (SM) and recommendations that will empower
cross-functional laboratory stakeholders to implement changes that can help
improve the diagnosis of SM.
Image Credits: [do_widget id=enhancedtextwidget-12].
AMP CASE REPORTS
* AMP CASE REPORT: USE OF MOLECULAR TECHNIQUES TO SOLVE A CHALLENGING CASE OF
PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA
April 2024—Primary cutaneous marginal zone lymphoma (PCMZL) is a newly
recognized, distinctive subtype of non-Hodgkin’s lymphoma. This low-grade
lymphoma predominantly presents as papules or nodules within the skin of
middle-aged adults. Formerly grouped under the extranodal marginal zone
lymphoma (EMZL) category, the World Health Organization’s fifth edition
classification of hematolymphoid tumors now recognizes PCMZL as a distinct
entity.
Read More »
* AMP CASE REPORT: ACUTE MYELOID LEUKEMIA WITH HYPERDIPLOIDY
* AMP CASE REPORT: POTENTIAL VON HIPPEL-LINDAU SYNDROME IN A PATIENT WITH
NEGATIVE GERMLINE TESTING
* AMP CASE REPORT: IDENTIFICATION OF MULTIPLE GERMLINE CANCER PREDISPOSING GENE
VARIANTS IN A SINGLE PATIENT DURING TUMOR SEQUENCING ANALYSIS
* AMP CASE REPORT: LUNG MICROPAPILLARY ADENOCARCINOMAS REVISITED
MAY 2024
* CLIMATE OF CONCERN OVER FUNGAL INFECTIONS
May 2024—If anything keeps Arturo Casadevall, MD, PhD, lying awake at night,
it’s the frogs. And the bats. Also, the patients (relatively few, at least
for now) who are affected by invasive fungal diseases. Dr. Casadevall is a
microbiologist and infectious diseases expert in the Johns Hopkins Division
of Infectious Diseases, Department of Medicine, and the Bloomberg School of
Public Health, where he’s a professor of medicine and chairs the Department
of Molecular Microbiology and Immunology. In his waking hours, he looks
deeply and broadly at the natural world and how the disturbing growth of
fungal infections might impact the medical world. Though the arrows haven’t
hit the bull’s-eye, they seem to be flying in that direction, says Dr.
Casadevall, who has written widely on this topic, including “Immunity to
Invasive Fungal Diseases.” In a recent interview with CAP TODAY, Dr.
Casadevall spoke about how he and others in the field are thinking about how
medicine might respond to this potential threat.
Read More »
* DIGGING INTO THE INTERPRETATION OF TSH RESULTS
May 2024—In a time of wellness testing and high rates of levothyroxine
prescribing for hypothyroidism, it may also be time to rethink TSH test
result interpretation.
* CORE LAB EFFICIENCIES IN MONOCLONAL GAMMOPATHY TESTING
May 2024—Many laboratories have brought order to chaos in test ordering by
launching initiatives to do so, for cost and staff savings and patient care
benefits. TriCore is one—it set its sights on orders for monoclonal
gammopathies.
* LUPUS ANTICOAGULANT—PROFICIENCY TEST AND PREANALYTICS
May 2024—What is a lupus anticoagulant (LA)? LA is somewhat of a misnomer.
Many patients with this condition do not have systemic lupus erythematosus
(SLE) and usually do not bleed. However, the in vitro phenomenon was
originally described in patients with SLE, as well as other autoimmune
disorders—thus use of the term “lupus,” and this does often lead to prolonged
in vitro coagulation testing—thus use of the term “anticoagulant.”
Image Credits: [do_widget id=enhancedtextwidget-12].
IN EVERY ISSUE
* FROM THE PRESIDENT’S DESK
May 2024—You may have read my column in the March issue about how the CAP is
taking care of the next generation of pathologists by helping and engaging
our new-in-practice colleagues. If you’re a more seasoned pathologist, you
may be wondering: What about me?
Read More »
* CLINICAL PATHOLOGY SELECTED ABSTRACTS
May 2024—Massive hemorrhage is a major cause of death in children, and the
mortality rate from life-threatening hemorrhage is estimated to be 20 to 51
percent. To counter this high mortality rate, clinicians have sought to
standardize massive transfusion protocols and hemostatic resuscitation,
ensuring that protocols support balanced blood-based resuscitation or the use
of low titer group O whole blood, or both. These protocols may include using
the lysine analogue antifibrinolytics tranexamic acid (TXA) and epsilon
aminocaproic acid (EACA) in children with life-threatening hemorrhage (LTH).
However, use of these antifibrinolytics is much more common in adult trauma
patients. Study data suggest that TXA may increase survival outcomes in
adults with traumatic injury, postpartum hemorrhage, nontraumatic
intracranial hemorrhage, and all-cause bleeding.
* ANATOMIC PATHOLOGY SELECTED ABSTRACTS
May 2024—The Bethesda System for Reporting Thyroid Cytopathology described
four subclasses of atypia within the atypia of undetermined significance
category: nuclear (AUS-Nuc), architectural (AUS-A), oncocytic (AUS-Onc), and
atypia not otherwise specified (AUS-NOS). Accumulating evidence supports the
use of a binary AUS subclassification scheme based primarily on the presence
of nuclear atypia only. The authors conducted a study to compare the risk
stratification of binary versus four-tier AUS subclassification systems among
AUS nodules with molecular or histologic follow-up, or both. The study
included thyroid aspirates classified as AUS and tested using Afirma
(Veracyte Inc.) between June 2013 and July 2021. Histological classification
was considered the final outcome for resected nodules.
* MOLECULAR PATHOLOGY SELECTED ABSTRACTS
May 2024—Immunotherapy has revolutionized cancer treatment by recruiting the
patient’s immune system to detect and destroy cancer cells. Immunotherapy
often involves immune checkpoint blockade (ICB) agents, which target negative
regulators of T-cell activation, such as cytotoxic T lymphocyte-associated
protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed
death-ligand 1 (PD-L1). Although ICB is used to treat a variety of cancer
types, patients’ response to therapy is often unpredictable, and biomarkers
such as tumor mutation burden, mismatch repair deficiency, and IHC for PD-L1
have limitations for assessing ICB response. Consequently, there is great
interest in discovering additional biomarkers that will improve the ability
to predict clinical response to ICB. Recent studies have explored the
hypothesis that there may be a correlation between a person’s gut microbiome
and therapeutic response.
CAP TODAY Website
CAP TODAY Digital Edition
CAP TODAY Webinars
Contact Us
CAP TODAY
X